Therefore, our research was the first uncovered the novel circSLC6A6/miR-1265/C2CD4A/p53 axis in the CRC growth and its molecular mechanism to provide a promising therapeutic targets of CRC. This evidence concerns the gene TP53 and colorectal carcinoma.